Edwards Lifesciences Long-Term Debt increased by 0.0% to $598.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.1%, from $597.80M to $598.50M. Over 5 years (FY 2020 to FY 2025), Long-Term Debt shows relatively stable performance with a 0.1% CAGR.
An increase indicates higher financial leverage, which can amplify returns on equity but also increases interest expense and financial risk.
Loans and financial obligations with a maturity period exceeding one year, typically consisting of corporate bonds and n...
Capital-intensive firms or those with aggressive share buyback programs often carry higher long-term debt than asset-light competitors.
long_term_debt| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $595.40M | $595.50M | $595.70M | $595.90M | $596.00M | $596.20M | $596.30M | $596.50M | $596.70M | $596.80M | $597.00M | $597.20M | $597.30M | $597.50M | $597.70M | $597.80M | $598.00M | $598.20M | $598.30M | $598.50M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% |